Search Results 651-660 of 17000 for pharmacogenetics

  1. Faculty - Department of Molecular Pharmacology and Experimental Therapeutics Research

    View research faculty in the Department of Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic.

  2. Medical Research & Education - Mayo Clinic News Network

    The Mayo Clinic Center for Individualized Medicine has achieved a milestone, finishing study recruitment after enrolling more than 100,000 participants in a ...

  3. A Study to Determine if Differences in the Microbe Environment of the Intestines Connects to the Effects of Obesity on Intestinal Stem Cells - Mayo Clinic

    About this study. New studies are revealing how a high-fat diet could be making the cells of the intestinal lining more likely to become cancerous.

  4. Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer - Mayo Clinic

    Taselisib is a PI3K inhibitor. The PI3K pathway is involved is cancer growth. Androgen may cause the growth of tumor cells. Enzalutamide may stop the growth of ...

  5. Abnormal Glycosylation on the Hypothalamic-Pituitary Adrenal and -Gonadal Axes and Bone Health in Patients with Congenital Disorders of Glycosylation - Mayo Clinic

    About this study. The objectives of this study are to characterize the endocrine phenome of 60 patients with PMM2-CDG through a cross-sectional measurement ...

  6. Clinical trials - Oncology (Medical)

    ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...

  7. A StudyStudy of Healthcare Provider Perceptions on Family Caregivers in Clinical Practice

    About this study. This study seeks to understand providers' perspectives on integrating a routine caregiver assessment tool into clinical practice.

  8. Erlotinib with or without Bevacizumab in Treating Patients with Stage IV Non-Small Cell Lung Cancer with EGFR Mutations - Mayo Clinic

    Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Bevacizumab blocks the ability of tumors to grow new blood vessels and ...

  9. A Study to Evaluate the Patterns of Use of Biological Agents and Risk Factors for Discontinuation of Agents in Pediatric Crohn’s Disease (CD) and Ulcerative Colitis (UC) within the Pediatric Population - Mayo Clinic

    This population will be queried for biologic use prior to age 18. The study population for the remainder of the study will be all CD and UC patients in ICN who ...

  10. Clinical trials - Oncology (Medical)

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...